



Sample Management Technology Enabling Scientific Breakthroughs

Robin Vacha, SVP and General Manager, Life Sciences Products





Sample Management Technology Enabling Scientific Breakthroughs

2

AZENTA

Azenta Life Sciences Products at a Glance



Products Revenue Breakdown





FY 2021


25% Automated Storage Systems

\$200M FY2021 revenue Auto store installed ~500M base sample capacity >2,000 Customer accounts

Key Metrics

Well-Positioned in \$4B Global Products Market





Key Market Drivers

- Life science R&D investment growing
- Automation driving increased throughput
- Precision medicine requires new capabilities



Azenta has 5% share and is set to outgrow the market



Our Product Portfolio Provides Complete Sample Management Solutions

Automated Sample Stores

Pharma & Biologics	Cell & Gene		
 BioStore[™] (-80°C) 	 BioStore[™] Cryo (-190°C) 		
 SampleStore[™] (-20°C) 	 CryoPod[®] transport system 		

- Capacity from <200K samples to over 20 million
- Cryo LN₂ filling station

- Sample FormattingServiceConsumables &
InstrumentsValue Add ServiceImage: Consumable of the service of the servic
 - Maintenance and upgrades
 - Sample migration
 - Reformatting
 - Install/Operating/Production Qualification (IOPQ)

We protect sample integrity and accelerate the pace of research

Sample tubes for

PCR product lines

applications

automated and critical

Controlled Rate Freezing

5

Biologics Small Molecule Cell & Gene -20°C -80°C Ambient -196°C Active Cells and Tissue Pharmaceutical DNA Blood RNA Ingredients Thermal integrity Large collections ٠ • Sample security • High throughput • **BioStore BioStore III Cryo** SampleStore


Sample Formatting

AZENTA LIFE SCIENCES

Azenta Technology Excels in the Most Difficult Applications

Automated Stores – Insights Into Scale and Technology





https://rewatchable.wistia.com/medias/wmldvuxvxx

© 2021 Brooks Automation, Inc. • Proprietary Information

CASE STUDY: Complex Sample Collection at Large Consumer Genomics Company

The Situation

• Tens of millions of DNA samples needed to be formatted, protected, stored, and rapidly retrieved

Our Solution

- Full Azenta Life Sciences Products ecosystem
 - BioStore Automated Storage System
 - Sample tubes
 - Formatting instrumentation
 - Reformatting service
- Unleashes value of sample collection and enabled new business model






Storage and Protection of High Value Master Cell Lines

The Situation


 Need to protect and store Master Cell Lines. Maintaining thermal integrity and restricting access key to long term viability

Our Solution

- Full Azenta Life Sciences Products ecosystem
 - BioStore III Cryo Automated Store
 - CryoPod transport module
 - Advanced software module managing access and security
- Not Covid specific. Master Cell Lines serve as the foundation of future scientific research








Sample Management Technology Enabling Scientific Breakthroughs

© 2021 Brooks Automation, Inc. • Proprietary Information


AZENTA

Three Key Growth Drivers





Sample Collections Are Growing in Size and Complexity, Increasing Demand for Automated Solutions



- Automation drives increased efficiency as sample collections grow
- Precision medicine is accelerating sample storage volume and complexity


AZENTA

Cell and Gene Solutions Are Accelerating – Just at the Beginning of Therapy Approvals

Cryo Automation Adoption Increasing in the Cell & Gene Therapy Market

- Building installed base in cell and gene since 2016
- Technology is a critical enabler for cold chain management of therapies
- Ramping as cell and gene investments grow









Azenta Ecosystem Creating New Opportunities






Genomics Creates Tight Customer Bond in Early-stage Research





Automated Storage Creates Tight Customer Bond in Clinical and Manufacturing Phases





Sample Management Technology Enabling Scientific Breakthroughs


AZENTA

Driving Continued Performance



▶20-24%

2024E



* Non-GAAP financial measure – See reconciliation tables © 2021 Brooks Automation, Inc. • Proprietary Information

2024 Target Model – Azenta Products



Drivers

Strong Market Growth	•	Global sample growth with trends toward automation and cryogenics
Differentiated Technology	•	Unique lab automation capabilities well-positioned for CGT applications
Leverage End-to-End Azenta Ecosystem	•	Deep customer connections at every stage of development and distribution

Operating Margin Expansion • Well positioned to leverage future volumes

Target Model

Azenta Products	FY21	FY24	Growth / Change
Revenue	\$200M	\$280-310M	12-16% CAGR
Gross Margin*	47%	47-49%	+Flat to 2pts
EBITDA Margin*	17%	20-24%	+3 to 7 pts

We are a critical enabler for adoption and ramp

of cell and gene therapies

Proven execution delivering profitable growth

© 2021 Brooks Automation, Inc. • Proprietary Information

1

AZENTA

Right Technology in the Right Markets with Strong Execution

Our technology is differentiated with innovation for the most difficult applications

Sample collections continue to grow and will require automation to unlock their potential





